CD20: a target antigen for immunotherapy of autoimmune diseases.
about
Involvement of B cells in non-infectious uveitisCAR-modified T-cell therapy for cancer: an updated review.An update on the management of chronic inflammatory demyelinating polyneuropathy.Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system.The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative MedicineLong-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine.Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigenImmunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease.Regaining tolerance to a self-antigen by the modified vaccination technique.Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review.Immunological evaluation of predicted linear B-cell epitopes of human CD20 antigen.Biological therapy in systemic lupus erythematosus.Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.
P2860
Q26766611-85DB2BBC-F634-45D3-BE4E-7B189BD2E8D2Q34044213-8F418512-460E-4765-AA52-7120DA5AFB47Q34645179-2F088BB7-5FB4-4F6F-AE4F-A15BDA447086Q35611416-226E6E7C-B23A-490C-9370-915170723EAEQ35928383-9772BDB2-6F6D-42F2-9E8A-2E7678FB69C6Q36151665-BD4B6616-E991-4AC1-9851-98F9946989F6Q36327992-2643C93A-8036-4484-B3D2-598434428D36Q36469965-6F5B6086-CCB2-48BE-80ED-26FC07928D30Q36707550-30188B54-3CA0-44CA-8BBB-7773F923C803Q36777171-CFA33BF3-865F-46C6-90A3-F001079BAD8EQ38027890-15B0663B-7EDF-48D2-B647-3D6EB1BED94AQ38072388-13F7224F-A3E9-4688-B0DF-57B9F7B3FD93Q38218786-FF3AE511-ED4A-4CE5-916F-13FBE9C13870Q38418254-EE83B95A-84DA-4A79-9700-35D9D3FF0A4AQ39166301-998FAF78-866F-4233-8D3D-5DF0A23AD7F3Q42141973-FAD4ABF1-4874-4595-8584-FC613DC9BCE3Q44889686-72F9AA4F-00A7-475C-980B-0C6EBC20E9ECQ45864886-5E3F3198-EB89-4AE3-9111-DB1D900FB106Q52985913-4DA2EF9C-F429-437A-B1A2-099EC6D2CB66
P2860
CD20: a target antigen for immunotherapy of autoimmune diseases.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
CD20: a target antigen for immunotherapy of autoimmune diseases.
@ast
CD20: a target antigen for immunotherapy of autoimmune diseases.
@en
type
label
CD20: a target antigen for immunotherapy of autoimmune diseases.
@ast
CD20: a target antigen for immunotherapy of autoimmune diseases.
@en
prefLabel
CD20: a target antigen for immunotherapy of autoimmune diseases.
@ast
CD20: a target antigen for immunotherapy of autoimmune diseases.
@en
P2093
P1433
P1476
CD20: a target antigen for immunotherapy of autoimmune diseases.
@en
P2093
Franco Dammacco
Marcella Prete
Maria Antonietta Caragnano
P304
P356
10.1016/J.AUTREV.2005.04.004
P577
2005-11-01T00:00:00Z